8-K: Salarius Regains Nasdaq Compliance, Advances Decoy Merger

Salarius Pharmaceuticals announced it has regained full compliance with Nasdaq listing requirements, a critical step towards its planned merger with Decoy Therapeutics.

Summary

• Salarius Pharmaceuticals, Inc. (SLRX) regained compliance with Nasdaq Listing Rule 5550(b)(1), the minimum stockholders' equity requirement, on October 10, 2025.
• This follows the company's announcement on September 9, 2025, that it had regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Requirement.
• Salarius is now fully compliant with all Nasdaq listing requirements.
• Nasdaq will subject Salarius to a Mandatory Panel Monitor for a period of one year from October 10, 2025.
• If Salarius falls out of compliance with the Equity Standard again during the monitoring period, Nasdaq will issue a delisting determination letter without further compliance opportunities.
• Regaining compliance is a critical step in the planned merger with Decoy Therapeutics, Inc., a privately held preclinical biopharmaceutical company, which was announced on January 13, 2025.
• The combined company will be named Decoy Therapeutics and will be led by Decoy's co-founders and executives, along with Salarius's acting CEO and CFO, Mark Rosenblum.
• The combined entity plans to advance Decoy's pipeline of peptide conjugate therapeutics, including a pan-coronavirus antiviral, and incorporate Salarius's SP-3164 into a new peptide-based PROTACS drug candidate.

Sentiment

Score: 7

Explanation: The regaining of full Nasdaq compliance is a major positive, removing an immediate delisting threat and enabling the strategic merger. The merger itself presents a promising pipeline and platform. However, the one-year mandatory monitoring period with strict delisting consequences if the Equity Standard is breached again introduces a notable element of risk and uncertainty.

Positives

• Regained compliance with Nasdaq's minimum stockholders' equity requirement (Rule 5550(b)(1)) on October 10, 2025.
• Previously regained compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)) on September 9, 2025.
• Now fully compliant with all Nasdaq listing requirements, removing an immediate delisting threat.
• The compliance is a critical step in advancing the planned merger with Decoy Therapeutics, expected to facilitate multiple value-creating inflection points.
• Decoy's pipeline targets unmet needs in respiratory infectious diseases and gastroenterology (GI) oncology indications.
• The combined company intends to incorporate Salarius's oral small molecule protein degrader SP-3164 into a highly targeted peptide-based PROTACS drug candidate.
• Decoy has attracted financing from institutional investors and significant non-dilutive capital from various sources, including the Massachusetts Life Sciences Seed Fund, Google AI startup program, NVIDIA Inception program, and BARDA QuickFire Challenge award funding.

Negatives

• Subject to a Mandatory Panel Monitor for one year from October 10, 2025.
• If found out of compliance with the Equity Standard again during the monitoring period, a delisting determination letter will be issued without the opportunity for a new compliance plan or additional time.

Risks

• The conditions to the closing of the proposed merger may not be satisfied, including uncertainties as to the timing of the consummation.
• The ability of each of Salarius and Decoy to consummate the merger.
• Risks related to the combined company's ability to satisfy the initial listing standards in the required timeframe.
• Risks related to Salarius's ability to estimate and manage its operating expenses and its expenses associated with the proposed merger pending the closing.
• Risks that the combined company will not achieve the synergies expected from the proposed merger.
• Risks that Salarius and the combined company will not obtain sufficient financing to execute on their business plans.
• Risks related to Decoy's products and development plans, including unanticipated issues with any Investigational New Drug (IND) application process.
• Risks related to the potential of the IMP3ACT platform.
• Actual results could differ materially from forward-looking statements due to various factors.

Future Outlook

The combined company, to be named Decoy Therapeutics, expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) within the next 12 months. Progress is also anticipated for other programs, including a broad-acting antiviral against flu, COVID-19, and respiratory syncytial virus (RSV), and a peptide drug conjugate targeting GI cancers. Additionally, data may be reported from an investigator-initiated Phase 1/2 clinical study at MD Anderson Cancer Center evaluating Salarius's seclidemstat as a potential treatment for myelodysplastic syndrome and chronic myelomonocytic leukemia.

Management Comments

• "Salarius is now fully compliant with all Nasdaq listing requirements, marking another critical step in our planned merger with Decoy Therapeutics."

Industry Context

The merger combines a clinical-stage oncology company (Salarius) with a preclinical biopharmaceutical company focused on peptide conjugate therapeutics for infectious diseases and GI cancers (Decoy). This strategic move diversifies the combined entity's pipeline into both oncology and infectious diseases, leveraging Decoy's IMP3ACT™ platform, which utilizes machine learning and AI for rapid drug design. This aligns with broader industry trends towards advanced drug discovery technologies and addressing a wider range of unmet medical needs, positioning the new company to potentially capitalize on multiple therapeutic areas.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact from regaining Nasdaq compliance, reducing delisting risk. Potential for value creation from the planned merger with Decoy's pipeline and platform. Risk of delisting if compliance is lost again during the one-year monitoring period.
• Employees: New leadership structure for the combined company, potentially impacting roles and responsibilities.
• Customers/Patients: Potential for new therapeutic options from Decoy's pipeline in respiratory infectious diseases and GI oncology, and continued development of Salarius's seclidemstat.

Next Steps

• Advance Decoy's lead asset, a pan-coronavirus antiviral, to an Investigational New Drug (IND) application filing with the FDA within the next 12 months.
• Make progress with other Decoy programs, including a broad-acting antiviral against flu, COVID-19, and RSV, and a peptide drug conjugate targeting GI cancers.
• Report data from an investigator-initiated Phase 1/2 clinical study at MD Anderson Cancer Center evaluating Salarius's seclidemstat.
• Consummate the planned merger with Decoy Therapeutics.

Key Dates

Recommendation

While regaining Nasdaq compliance is a significant positive, removing an immediate delisting threat and enabling the merger, the one-year mandatory monitoring period introduces substantial risk. The success of the combined entity hinges on the successful integration of the merger, the advancement of Decoy's preclinical pipeline, and the ability to secure future financing, all of which carry inherent uncertainties. The strategic rationale for the merger is sound, but the execution risks and the strict Nasdaq monitoring warrant a cautious "Hold" stance until more clarity emerges on the combined company's operational progress and financial stability.

Keywords

Salarius Pharmaceuticals, SLRX, Decoy Therapeutics, Nasdaq compliance, merger, biopharmaceutical, peptide conjugate, IMP3ACT platform, oncology, infectious disease, drug development, delisting risk, corporate governance